[HTML][HTML] Correlates of protection against SARS-CoV-2 in rhesus macaques
Recent studies have reported the protective efficacy of both natural 1 and vaccine-induced
2 , 3 , 4 , 5 , 6 – 7 immunity against challenge with severe acute respiratory syndrome …
2 , 3 , 4 , 5 , 6 – 7 immunity against challenge with severe acute respiratory syndrome …
DNA vaccine protection against SARS-CoV-2 in rhesus macaques
…, F Wegmann, EA Bondzie, G Dagotto, MS Gebre… - Science, 2020 - science.org
The global coronavirus disease 2019 (COVID-19) pandemic caused by severe acute respiratory
syndrome coronavirus 2 (SARS-CoV-2) has made the development of a vaccine a top …
syndrome coronavirus 2 (SARS-CoV-2) has made the development of a vaccine a top …
[HTML][HTML] Single-shot Ad26 vaccine protects against SARS-CoV-2 in rhesus macaques
A safe and effective vaccine for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
may be required to end the coronavirus disease 2019 (COVID-19) pandemic 1 , 2 , 3 , 4 …
may be required to end the coronavirus disease 2019 (COVID-19) pandemic 1 , 2 , 3 , 4 …
SARS-CoV-2 infection protects against rechallenge in rhesus macaques
…, P Abbink, EA Bondzie, G Dagotto, MS Gebre… - Science, 2020 - science.org
An understanding of protective immunity to severe acute respiratory syndrome coronavirus 2
(SARS-CoV-2) is critical for vaccine and public health strategies aimed at ending the global …
(SARS-CoV-2) is critical for vaccine and public health strategies aimed at ending the global …
Immunogenicity of COVID-19 mRNA vaccines in pregnant and lactating women
…, C Bradshaw, C Jacob-Dolan, J Feldman, M Gebre… - Jama, 2021 - jamanetwork.com
Importance Pregnant women are at increased risk of morbidity and mortality from COVID-19
but have been excluded from the phase 3 COVID-19 vaccine trials. Data on vaccine safety …
but have been excluded from the phase 3 COVID-19 vaccine trials. Data on vaccine safety …
Immunogenicity of the Ad26. COV2. S Vaccine for COVID-19
…, K McMahan, LH Tostanoski, J Yu, MS Gebre… - Jama, 2021 - jamanetwork.com
Importance Control of the global COVID-19 pandemic will require the development and
deployment of safe and effective vaccines. Objective To evaluate the immunogenicity of the Ad26…
deployment of safe and effective vaccines. Objective To evaluate the immunogenicity of the Ad26…
[HTML][HTML] Durable humoral and cellular immune responses 8 months after Ad26. COV2. S vaccination
Durability of Response after Ad26.COV2.S Vaccination In this study, investigators measured
immune responses in 20 participants who had received either one or two doses of the Ad26.…
immune responses in 20 participants who had received either one or two doses of the Ad26.…
[HTML][HTML] Ad26 vaccine protects against SARS-CoV-2 severe clinical disease in hamsters
Coronavirus disease 2019 (COVID-19) in humans is often a clinically mild illness, but some
individuals develop severe pneumonia, respiratory failure and death 1 , 2 , 3 – 4 . Studies of …
individuals develop severe pneumonia, respiratory failure and death 1 , 2 , 3 – 4 . Studies of …
[PDF][PDF] Novel approaches for vaccine development
MS Gebre, LA Brito, LH Tostanoski, DK Edwards… - Cell, 2021 - cell.com
Vaccines are critical tools for maintaining global health. Traditional vaccine technologies
have been used across a wide range of bacterial and viral pathogens, yet there are a number …
have been used across a wide range of bacterial and viral pathogens, yet there are a number …
[HTML][HTML] Optimization of non-coding regions for a non-modified mRNA COVID-19 vaccine
The CVnCoV (CureVac) mRNA vaccine for severe acute respiratory syndrome coronavirus-2
(SARS-CoV-2) was recently evaluated in a phase 2b/3 efficacy trial in humans 1 . CV2CoV …
(SARS-CoV-2) was recently evaluated in a phase 2b/3 efficacy trial in humans 1 . CV2CoV …